Why Bio-Path Stock Is Climbing Today
Portfolio Pulse from Erica Kollmann
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher after announcing positive interim results from its Phase 2 study of prexigebersen for treating acute myeloid leukemia. The data showed the drug is well-tolerated and effective, leading to a 13.5% increase in stock price. Analysts have a bullish outlook with a 1-year price target of $40.
June 14, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path Holdings shares surged 13.5% following positive interim results from its Phase 2 study of prexigebersen for AML treatment. The drug showed good tolerance and efficacy, leading to bullish analyst ratings and a 1-year price target of $40.
The positive interim results from the Phase 2 study of prexigebersen indicate strong potential for the drug in treating AML, which has led to a significant increase in BPTH's stock price. The bullish analyst ratings and high price target further support a positive short-term outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100